Cargando…
Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction
OBJECTIVE: Atrial fibrillation (AF) and myocardial infarction (MI) are commonly comorbid and associated with adverse outcomes. Little is known about the impact of AF on quality of life and outcomes post-MI. We compared characteristics, quality of life and clinical outcomes in stable patients post-MI...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679122/ https://www.ncbi.nlm.nih.gov/pubmed/34911791 http://dx.doi.org/10.1136/openhrt-2021-001726 |
_version_ | 1784616450181300224 |
---|---|
author | Carnicelli, Anthony P Owen, Ruth Pocock, Stuart J Brieger, David B Yasuda, Satoshi Nicolau, Jose Carlos Goodman, Shaun G Cohen, Mauricio G Simon, Tabassome Westermann, Dirk Hedman, Katarina Andersson Sundell, Karolina Granger, Christopher B |
author_facet | Carnicelli, Anthony P Owen, Ruth Pocock, Stuart J Brieger, David B Yasuda, Satoshi Nicolau, Jose Carlos Goodman, Shaun G Cohen, Mauricio G Simon, Tabassome Westermann, Dirk Hedman, Katarina Andersson Sundell, Karolina Granger, Christopher B |
author_sort | Carnicelli, Anthony P |
collection | PubMed |
description | OBJECTIVE: Atrial fibrillation (AF) and myocardial infarction (MI) are commonly comorbid and associated with adverse outcomes. Little is known about the impact of AF on quality of life and outcomes post-MI. We compared characteristics, quality of life and clinical outcomes in stable patients post-MI with/without AF. METHODS/RESULTS: The prospective, international, observational TIGRIS (long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease) registry included 8406 patients aged ≥50 years with ≥1 atherothrombotic risk factor who were 1–3 years post-MI. Patient characteristics were summarised by history of AF. Quality of life was assessed at baseline using EQ-5D. Clinical outcomes over 2 years of follow-up were compared. History of AF was present in 702/8277 (8.5%) registry patients and incident AF was diagnosed in 244/7575 (3.2%) over 2 years. Those with AF were older and had more comorbidities than those without AF. After multivariable adjustment, patients with AF had lower self-reported quality-of-life scores (EQ-5D UK-weighted index, visual analogue scale, usual activities and pain/discomfort) than those without AF. CHA(2)DS(2)-VASc score ≥2 was present in 686/702 (97.7%) patients with AF, although only 348/702 (49.6%) were on oral anticoagulants at enrolment. Patients with AF had higher rates of all-cause hospitalisation (adjusted rate ratio 1.25 [1.06–1.46], p=0.008) over 2 years than those without AF, but similar rates of mortality. CONCLUSIONS: In stable patients post-MI, those with AF were commonly undertreated with oral anticoagulants, had poorer quality of life and had increased risk of clinical outcomes than those without AF. TRIAL REGISTRATION NUMBER: ClinicalTrials: NCT01866904. |
format | Online Article Text |
id | pubmed-8679122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86791222022-01-04 Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction Carnicelli, Anthony P Owen, Ruth Pocock, Stuart J Brieger, David B Yasuda, Satoshi Nicolau, Jose Carlos Goodman, Shaun G Cohen, Mauricio G Simon, Tabassome Westermann, Dirk Hedman, Katarina Andersson Sundell, Karolina Granger, Christopher B Open Heart Coronary Artery Disease OBJECTIVE: Atrial fibrillation (AF) and myocardial infarction (MI) are commonly comorbid and associated with adverse outcomes. Little is known about the impact of AF on quality of life and outcomes post-MI. We compared characteristics, quality of life and clinical outcomes in stable patients post-MI with/without AF. METHODS/RESULTS: The prospective, international, observational TIGRIS (long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease) registry included 8406 patients aged ≥50 years with ≥1 atherothrombotic risk factor who were 1–3 years post-MI. Patient characteristics were summarised by history of AF. Quality of life was assessed at baseline using EQ-5D. Clinical outcomes over 2 years of follow-up were compared. History of AF was present in 702/8277 (8.5%) registry patients and incident AF was diagnosed in 244/7575 (3.2%) over 2 years. Those with AF were older and had more comorbidities than those without AF. After multivariable adjustment, patients with AF had lower self-reported quality-of-life scores (EQ-5D UK-weighted index, visual analogue scale, usual activities and pain/discomfort) than those without AF. CHA(2)DS(2)-VASc score ≥2 was present in 686/702 (97.7%) patients with AF, although only 348/702 (49.6%) were on oral anticoagulants at enrolment. Patients with AF had higher rates of all-cause hospitalisation (adjusted rate ratio 1.25 [1.06–1.46], p=0.008) over 2 years than those without AF, but similar rates of mortality. CONCLUSIONS: In stable patients post-MI, those with AF were commonly undertreated with oral anticoagulants, had poorer quality of life and had increased risk of clinical outcomes than those without AF. TRIAL REGISTRATION NUMBER: ClinicalTrials: NCT01866904. BMJ Publishing Group 2021-12-15 /pmc/articles/PMC8679122/ /pubmed/34911791 http://dx.doi.org/10.1136/openhrt-2021-001726 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Coronary Artery Disease Carnicelli, Anthony P Owen, Ruth Pocock, Stuart J Brieger, David B Yasuda, Satoshi Nicolau, Jose Carlos Goodman, Shaun G Cohen, Mauricio G Simon, Tabassome Westermann, Dirk Hedman, Katarina Andersson Sundell, Karolina Granger, Christopher B Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction |
title | Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction |
title_full | Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction |
title_fullStr | Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction |
title_full_unstemmed | Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction |
title_short | Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction |
title_sort | atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction |
topic | Coronary Artery Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679122/ https://www.ncbi.nlm.nih.gov/pubmed/34911791 http://dx.doi.org/10.1136/openhrt-2021-001726 |
work_keys_str_mv | AT carnicellianthonyp atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT owenruth atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT pocockstuartj atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT briegerdavidb atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT yasudasatoshi atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT nicolaujosecarlos atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT goodmanshaung atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT cohenmauriciog atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT simontabassome atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT westermanndirk atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT hedmankatarina atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT anderssonsundellkarolina atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction AT grangerchristopherb atrialfibrillationandclinicaloutcomes1to3yearsaftermyocardialinfarction |